Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1951 1
1952 1
1959 1
1960 1
1961 1
1962 2
1963 1
1964 8
1966 5
1967 2
1968 2
1969 4
1970 8
1971 11
1972 5
1973 6
1974 7
1975 7
1976 10
1977 8
1978 8
1979 8
1980 15
1981 11
1982 6
1983 4
1984 8
1985 7
1986 6
1987 6
1988 6
1989 6
1990 8
1991 6
1992 6
1993 3
1994 5
1996 1
1998 4
1999 5
2000 3
2001 7
2002 3
2003 7
2004 10
2005 11
2006 13
2007 10
2008 8
2009 10
2010 8
2011 10
2012 12
2013 10
2014 9
2015 6
2016 12
2017 13
2018 14
2019 13
2020 13
2021 12
2022 11
2023 2
Text availability
Article attribute
Article type
Publication date

Search Results

423 results
Results by year
Filters applied: . Clear all
Page 1
Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL.
Northend M, Wilson W, Osborne W, Fox CP, Davies AJ, El-Sharkawi D, Phillips EH, Sim HW, Sadullah S, Shah N, Peng YY, Qureshi I, Addada J, Mora RF, Phillips N, Kuhnl A, Davies E, Wrench D, McKay P, Karpha I, Cowley A, Karim R, Challenor S, Singh V, Burton C, Auer R, Williams C, Cunningham J, Broom A, Arasaretnam A, Roddie C, Menne T, Townsend W. Northend M, et al. Among authors: davies aj. Blood Adv. 2022 May 10;6(9):2920-2926. doi: 10.1182/bloodadvances.2021005953. Blood Adv. 2022. PMID: 35020818 Free PMC article. No abstract available.
Natural Killer Cells Degenerate Intact Sensory Afferents following Nerve Injury.
Davies AJ, Kim HW, Gonzalez-Cano R, Choi J, Back SK, Roh SE, Johnson E, Gabriac M, Kim MS, Lee J, Lee JE, Kim YS, Bae YC, Kim SJ, Lee KM, Na HS, Riva P, Latremoliere A, Rinaldi S, Ugolini S, Costigan M, Oh SB. Davies AJ, et al. Cell. 2019 Feb 7;176(4):716-728.e18. doi: 10.1016/j.cell.2018.12.022. Epub 2019 Jan 31. Cell. 2019. PMID: 30712871 Free PMC article.
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA. Gopal AK, et al. Among authors: davies aj. N Engl J Med. 2014 Mar 13;370(11):1008-18. doi: 10.1056/NEJMoa1314583. Epub 2014 Jan 22. N Engl J Med. 2014. PMID: 24450858 Free PMC article. Clinical Trial.
Precision Medicine in DLBCL: Are We There Yet?
Davies AJ. Davies AJ. J Clin Oncol. 2021 Apr 20;39(12):1314-1316. doi: 10.1200/JCO.20.03531. Epub 2021 Feb 23. J Clin Oncol. 2021. PMID: 33621123 No abstract available.
Crystallization-induced diastereomer transformations.
Brands KM, Davies AJ. Brands KM, et al. Among authors: davies aj. Chem Rev. 2006 Jul;106(7):2711-33. doi: 10.1021/cr0406864. Chem Rev. 2006. PMID: 16836297 Review. No abstract available.
Primary mediastinal B-cell lymphoma.
Johnson PW, Davies AJ. Johnson PW, et al. Among authors: davies aj. Hematology Am Soc Hematol Educ Program. 2008:349-58. doi: 10.1182/asheducation-2008.1.349. Hematology Am Soc Hematol Educ Program. 2008. PMID: 19074109 Review.
Lactobacillus endocarditis.
Davies AJ, James PA, Hawkey PM. Davies AJ, et al. J Infect. 1986 Mar;12(2):169-74. doi: 10.1016/s0163-4453(86)93733-3. J Infect. 1986. PMID: 3084661
The trouble with T cells.
Davies AJ, Wallis VJ, Morrison WI. Davies AJ, et al. Lancet. 1990 Jun 30;335(8705):1574-6. doi: 10.1016/0140-6736(90)91389-r. Lancet. 1990. PMID: 1972497 Review. No abstract available.
423 results